Home » Stocks » CODX

Co-Diagnostics, Inc. (CODX)

Stock Price: $9.12 USD -1.42 (-13.47%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $9.15 +0.03 (0.33%) Jul 23, 7:56 PM
Market Cap 263.38M
Revenue (ttm) 93.03M
Net Income (ttm) 51.44M
Shares Out 28.66M
EPS (ttm) 1.73
PE Ratio 5.28
Forward PE 10.13
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $9.12
Previous Close $10.54
Change ($) -1.42
Change (%) -13.47%
Day's Open 9.86
Day's Range 8.92 - 9.90
Day's Volume 2,256,912
52-Week Range 7.01 - 30.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Co-Diagnostics Inc (NASDAQ:CODX) shares are trading higher by 26.3% at $10.99 Thursday afternoon. The stock spiked earlier following reports suggesting the Biden Administration will announce it is direc...

2 days ago - Benzinga

SALT LAKE CITY, July 22, 2021  /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

2 days ago - PRNewsWire

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do...

4 days ago - Zacks Investment Research

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Other stocks mentioned: BNTX, MRNA, NVAX, PFE, VXRT
5 days ago - The Motley Fool

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

3 weeks ago - Zacks Investment Research

SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ann...

1 month ago - PRNewsWire

SALT LAKE CITY, June 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...

1 month ago - PRNewsWire

Some of the stocks that may grab investor focus today are: Walt Disney Co (NYSE: DIS) reported upbeat earnings for its second quarter, while sales missed expectations. Disney+ ended the second quarter w...

Other stocks mentioned: COIN, DDS, DIS, PLT
2 months ago - Benzinga

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Co-Diagnostics (NASDAQ:CODX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 620.00% year over year to $0.26, which b...

2 months ago - Benzinga

Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the co...

2 months ago - Proactive Investors

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, annou...

2 months ago - PRNewsWire

SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...

2 months ago - PRNewsWire

Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) ...

2 months ago - Proactive Investors

SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...

2 months ago - PRNewsWire

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other stocks mentioned: BDSI, KMDA, SURF, VMD
3 months ago - GuruFocus

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Austra...

3 months ago - Proactive Investors

SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced to...

3 months ago - PRNewsWire

CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bai...

3 months ago - InvestorPlace

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...

3 months ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...

3 months ago - Proactive Investors

SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, a...

3 months ago - PRNewsWire

Co-Diagnostics CEO discusses coronavirus testing: We believe robust testing is key to normalizing

YouTube video

coronavirustesting Yahoo Finance's Adam Shapiro and Seana Smith spoke with Co-Diagnostics CEO Dwight Egan about the company's outlook and the latest coronavirus testing methods.

3 months ago - Yahoo Finance

Analysts following this coronavirus stock have darkened their post-pandemic outlook.

3 months ago - The Motley Fool

The company's recent struggles on the stock market continue.

3 months ago - The Motley Fool

With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...

Other stocks mentioned: DOCU
3 months ago - 24/7 Wall Street

Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...

3 months ago - Proactive Investors

Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...

3 months ago - Proactive Investors

Investors didn't like what they heard in the company's fourth-quarter update.

3 months ago - The Motley Fool

The company missed earnings expectations and hinted at slowing growth in 2021.

3 months ago - The Motley Fool

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales.  That's a huge turnaround for ...

3 months ago - Proactive Investors

Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which miss...

3 months ago - Benzinga

SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

3 months ago - PRNewsWire

CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings ...

3 months ago - InvestorPlace

SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

4 months ago - PRNewsWire

SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...

4 months ago - PRNewsWire

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Other stocks mentioned: FLGT, JNJ, MRNA, NVAX
4 months ago - The Motley Fool

SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...

4 months ago - PRNewsWire

SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...

4 months ago - PRNewsWire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, AYTU, CRTX, DVAX, SRNE
4 months ago - Investors Business Daily

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...

4 months ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...

4 months ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health p...

Other stocks mentioned: WBA
4 months ago - Proactive Investors

Its technology underpins a coronavirus test that's about to get much wider distribution.

5 months ago - The Motley Fool

Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer...

Other stocks mentioned: WBA
5 months ago - Proactive Investors

With the latter appointment, the company's founder moves into a more advisory role.

5 months ago - The Motley Fool

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice pres...

5 months ago - Proactive Investors

SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced tod...

5 months ago - PRNewsWire

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also pro... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 12, 2017
CEO
Dwight Egan
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
CODX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Co-Diagnostics stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 152.19% from the latest price.

Price Target
$23.00
(152.19% upside)
Analyst Consensus: Buy